";s:4:"text";s:3996:" The dose of terazosin was titrated to 5 mg. per day for a 1-month interval, provided adverse drug reactions were not observed.
The mean IC50 corrected for prazosin, phentolamine and yohimbine was 7.8 × 10⁻¹⁰ M., 6.0 × 10⁻¹⁰ M. and 2.1 × 10⁻¹⁰ M. The rank order of the IC50 corrected values indicates that alpha1 binding sites were measured under the assay conditions. Symptom score assessment is now used in BPH, although a number of different instruments are available. reductase inhibitor drugs have been the most favorite agents in the medical treatment of benign prostate hyperplasia.
The improvements were not only in voiding symptoms but also in storage symptoms. Alfuzosin (especially the sustained release formulation) and tamsulosin (modified release formulation 0.4 mg) seem to be better tolerated than terazosin and doxazosin. The clinical response to alpha blockade in BPH is related to the area density of prostate smooth muscle.The adrenergic and cholinergic receptors of the human prostatic capsule, prostatic “adenoma”, and bladder neck, were investigated by the in-vitro isometric technique. The adrenergic response is variable in the true bladder neck muscle, but is present and strong in the trigonal muscle. The peak and mean urinary flow rates improved by 42% and 48%, respectively, after 2 months of terazosin therapy.
Treatment with alpha1-blockers appears to be useful for diabetic patients with BPH and its effectiveness is not altered by the duration of diabetes.
The percentage of patients that withdrew due to bothersome side effects with alfuzosin and tamsulosin 0.4 mg was comparable to that with placebo (about 4-10%) whereas in the terazosin and doxazosin studies an additional 4-10% of patients dropped out because they did not tolerate the therapy. The United States experience with this drug is reviewed in the present report. In conclusion, each of the four medications is a possible treatment option for BPH, but we believe alfuzosin and tamsulosin are the better choice. A new and interesting observation is that patients receiving certain α1-adrenoceptor blockers notice improvement in their sexual function and in particular in the quality of their erectile response. Indirect comparison of data derived from the placebo-controlled studies involving 6,333 patients and the data derived from the direct comparative studies involving 507 patients demonstrate that all alpha1-adrenoceptor antagonists (alfuzosin, terazosin, doxazosin and tamsulosin) produce comparable improvements in LUTS and urinary flow.
Intra‐ and intergroup differences of uroflowmetry parameters and blood pressures were tested by paired Of the 121 patients enrolled, 33, 42 and 46 were entered into the groups of prazosin, terazosin and tamsulosin, respectively.